Role of Centrum® Silver® in Improving Micronutrient Status in Older Men

NCT03004807

Last updated date
Study Location
Linus Pauling Science Center
Corvallis, Oregon, 97331, United States
Contact
541-737-8730

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

541-737-8730

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Vitamin Deficiency, Mineral Deficiency, Aging
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
70 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Participants must be willing to:

- Consume a multivitamin/mineral supplement or placebo tablet each day during the 6-month study period

- Fill out online food frequency questionnaires

- Refrain from taking dietary supplements (vitamins, minerals, certain antacids, energy drinks, fortified cereals, or nutritional shakes) other than those provided during the study, with an exception for vitamin D. Users of multivitamin supplements must agree to avoid taking these supplements for two months before the study begins.

- Refrain from taking acid-blockers during the course of the study.

- Wear an activity monitor about the wrist continuously for two one-week periods, except when exposed to water, before and during multivitamin supplementation.

- Give blood samples on 3 separate occasions

- Participate in cognitive testing procedures

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Currently taking supplements as recommended/ordered by a physician to correct a
nutritional deficiency, with an exception for vitamin D supplements


- Current or recent (two years) history of smoking (tobacco or marijuana)


- Dysphagia or difficulty swallowing.


- Bariatric (gastric bypass) surgery or serious chronic illness that might affect
absorption of multivitamins or minerals such as Crohn's disease, unmanaged celiac
disease, chronic diarrhea, ulcerative colitis, gastritis, or a diagnosis of
malabsorption syndrome.


- A diagnosis of cancer with chemotherapy or radiation treatment during the previous 5
years.


- Major surgery in the past 6 months or planned major surgery during the duration of the
study.


- Prior heart attack, stroke, or heart failure.


- Uncontrolled stage II hypertension (blood pressure above 159/99 mm Hg).


- A current diagnosis of kidney, liver, or thyroid disease.


- Diabetes (Type 1 or Type 2).


- History of hypoglycemia or low blood sugar.


- Hb1ac levels > 6.4%.


- Current use of certain drugs to control blood sugar, thyroid medications, anti-seizure
medication, anxiolytics, or antidepressants (see Post-Screen Drug Review).


- BMI < 18.5 or > 35


- History of psychological or neurological disorders, or a diagnosis of dementia.


- Head injury with loss of consciousness of > 5 minutes in the last 5 years.


- Chronic Migraines - More than fifteen headache days per month over a three month
period of which more than eight are migraines.


- Score < 26 on the mini-mental state exam.


- Present treatment for drug or alcohol problems.


- Habit of taking three or more alcoholic drinks per day.


- Corrected visual acuity worse than 20/50.


- Anyone who cannot handwrite a letter or move a computer joystick with one of their
hands.


- Cannot hear well enough to understand spoken instructions.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Vitamin Deficiency, Mineral Deficiency, AgingRole of Centrum® Silver® in Improving Micronutrient Status in Older Men
NCT03004807
  1. Corvallis, Oregon
Male
70 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Role of Centrum® Silver® in Improving Micronutrient Status in Older Men
Official Title  ICMJE Role of Centrum® Silver® in Improving Micronutrient Status in Older Men
Brief Summary Older adults are susceptible to vitamin and mineral deficiencies for a variety of reasons and have an increased demand for many of these micronutrients. Multivitamin/multimineral supplement offer a simple way for adults to improve nutrient intake, but their ability to measurably affect micronutrient status in older adults has never been explored. This study intends to recruit healthy, non-smoking men aged 70 years or older. After meeting entry criteria, subjects will be required to restrict the use of supplements and/or fortified foods. Two months after these restrictions have begun, subjects will come to the clinical research center to take cognitive tests, undergo activity monitoring, provide blood samples for nutrition testing, and take food frequency questionnaires. Subjects will then be randomized into one of two groups - one consuming a multivitamin/multimineral supplement (Centrum Silver Mens Formula); another consuming an inert placebo tablet. Subjects will consume 1 tablet each day for six months. After this period, subjects will return to the clinical research center and repeat cognitive tests, activity monitor, blood sampling, and food frequency questionnaires. These data will be assessed to determine if multivitamin consumption results in changes in various nutrients versus taking a placebo (primary outcomes), and may results in changes lipid and lipoprotein profiles, metabolic health, inflammation, blood pressure or cognitive function (secondary outcomes). The investigators expect that results of this study will add to the general understanding if multivitamin/multimineral formulas can improve nutrition status of older adults, and therefore have the capacity of altering markers of health.
Detailed Description

Older adults are at increased risk of various chronic diseases, in which inadequate levels of vitamins and minerals may play a significant role, including cardiovascular disease, Alzheimer's disease, liver disease, and cancer. Most adults in the United States do not meet the Recommended Dietary Allowance (RDA) or Adequate Intake (AI) of many vitamins and nutritionally-essential minerals from diet alone, including vitamins A, C, D, E and K, calcium, magnesium, and potassium. Older adults are particularly susceptible to micronutrient inadequacies because of limited absorption, increased requirements, or - in the case of vitamin D - decreased synthetic capacity in the skin. Thus, there is a strong rationale for supplementing the diets of older adults with a multivitamin/multimineral supplement, such as Centrum® Silver®. However, little is currently known about the bioavailability of the Centrum® Silver® formula in this age demographic.

Epidemiological studies and recent clinical trials have shown that use of multivitamin/mineral supplements has beneficial effects on disease risk in men, including those of advanced age. It is assumed that these benefits of multivitamin/mineral supplements are achieved through changes in nutrition status. However, it has never been documented if there are concomitant changes in micronutrient levels in individuals who consume these supplements. Furthermore, changes in nutritional status in older individuals taking multivitamin/multimineral supplements are a subject that has yet to be explored.

Therefore, this study seeks to recruit men who are in generally good health, 70 years of age or older, to assess their vitamin and mineral status before and after six months (approximately 24 weeks) of supplementation with Centrum® Silver®. The investigators hypothesize that consuming multivitamin/multimineral supplements everyday will result in measurable increases in the status of one or more vitamins or minerals in the body. Concentrations of several vitamins and minerals in blood samples will be performed, along with a general assessment of micronutrient status in white blood cells (primary outcomes). To see if these changes in nutrition status impact other aspects of human health, changes in lipid and lipoprotein profiles, antioxidant status, metabolic health, and inflammation and treatment differences in cognitive function will be assessed (secondary outcomes). Centrum® Silver® supplementation may or may not have any effect on these secondary outcomes, when compared to a placebo, unless there are measurable changes in the primary outcomes.

The expectation is that the results of this research will add to a general understanding of multivitamin/mineral supplements and how well they can improve the nutritional status of older adults. By employing direct and functional methods to assay for nutritional content, this study will determine how well these methods correlate and by using both assay methods unique insight into the mechanism(s) whereby multivitamin/multimineral supplements might or might not lead to improvements in health may be ascertained.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Condition  ICMJE
  • Vitamin Deficiency
  • Mineral Deficiency
  • Aging
Intervention  ICMJE
  • Dietary Supplement: Centrum Silver Mens' Formula
    Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
    Other Name: Centrum Silver Men
  • Other: Control
    A matching tablet to the dietary supplement, but without any active ingredients
    Other Name: Placebo Comparator
Study Arms  ICMJE
  • Experimental: Multivitamin
    Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
    Intervention: Dietary Supplement: Centrum Silver Mens' Formula
  • Placebo Comparator: Control
    Matching tablet to active multivitamin arm: 1/day
    Intervention: Other: Control
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 22, 2016)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2020
Estimated Primary Completion Date October 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Participants must be willing to:

  • Consume a multivitamin/mineral supplement or placebo tablet each day during the 6-month study period
  • Fill out online food frequency questionnaires
  • Refrain from taking dietary supplements (vitamins, minerals, certain antacids, energy drinks, fortified cereals, or nutritional shakes) other than those provided during the study, with an exception for vitamin D. Users of multivitamin supplements must agree to avoid taking these supplements for two months before the study begins.
  • Refrain from taking acid-blockers during the course of the study.
  • Wear an activity monitor about the wrist continuously for two one-week periods, except when exposed to water, before and during multivitamin supplementation.
  • Give blood samples on 3 separate occasions
  • Participate in cognitive testing procedures

Exclusion Criteria:

  • Currently taking supplements as recommended/ordered by a physician to correct a nutritional deficiency, with an exception for vitamin D supplements
  • Current or recent (two years) history of smoking (tobacco or marijuana)
  • Dysphagia or difficulty swallowing.
  • Bariatric (gastric bypass) surgery or serious chronic illness that might affect absorption of multivitamins or minerals such as Crohn's disease, unmanaged celiac disease, chronic diarrhea, ulcerative colitis, gastritis, or a diagnosis of malabsorption syndrome.
  • A diagnosis of cancer with chemotherapy or radiation treatment during the previous 5 years.
  • Major surgery in the past 6 months or planned major surgery during the duration of the study.
  • Prior heart attack, stroke, or heart failure.
  • Uncontrolled stage II hypertension (blood pressure above 159/99 mm Hg).
  • A current diagnosis of kidney, liver, or thyroid disease.
  • Diabetes (Type 1 or Type 2).
  • History of hypoglycemia or low blood sugar.
  • Hb1ac levels > 6.4%.
  • Current use of certain drugs to control blood sugar, thyroid medications, anti-seizure medication, anxiolytics, or antidepressants (see Post-Screen Drug Review).
  • BMI < 18.5 or > 35
  • History of psychological or neurological disorders, or a diagnosis of dementia.
  • Head injury with loss of consciousness of > 5 minutes in the last 5 years.
  • Chronic Migraines - More than fifteen headache days per month over a three month period of which more than eight are migraines.
  • Score < 26 on the mini-mental state exam.
  • Present treatment for drug or alcohol problems.
  • Habit of taking three or more alcoholic drinks per day.
  • Corrected visual acuity worse than 20/50.
  • Anyone who cannot handwrite a letter or move a computer joystick with one of their hands.
  • Cannot hear well enough to understand spoken instructions.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 70 Years and older   (Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Alexander J Michels, PhD541-737-8730[email protected]
Contact: Sandra Uesugi, RN541-737-3594[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03004807
Other Study ID Numbers  ICMJE WI211838
7158 ( Other Identifier: Oregon State University IRB )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Tory Hagen, Oregon State University
Study Sponsor  ICMJE Tory Hagen
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Tory M Hagen, PhDOregon State University
PRS Account Oregon State University
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP